LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

Search

Certara Inc

Open

BrancheGesundheitswesen

8.81 -0.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.61

Max

8.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.5M

1.5M

Verkäufe

46K

105M

KGV

Branchendurchschnitt

130.143

78.892

EPS

0.14

Gewinnspanne

1.458

Angestellte

1,487

EBITDA

-6.5M

23M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+41.28% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-428M

1.5B

Vorheriger Eröffnungskurs

9.6

Vorheriger Schlusskurs

8.81

Nachrichtenstimmung

By Acuity

94%

6%

359 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Certara Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Dez. 2025, 21:41 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

28. Dez. 2025, 23:57 UTC

Ergebnisse

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

28. Dez. 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Dez. 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28. Dez. 2025, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

28. Dez. 2025, 10:30 UTC

Akquisitionen, Fusionen, Übernahmen

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

26. Dez. 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26. Dez. 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26. Dez. 2025, 19:24 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26. Dez. 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26. Dez. 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26. Dez. 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26. Dez. 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26. Dez. 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26. Dez. 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26. Dez. 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26. Dez. 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26. Dez. 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26. Dez. 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26. Dez. 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. Dez. 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26. Dez. 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26. Dez. 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26. Dez. 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26. Dez. 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25. Dez. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25. Dez. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25. Dez. 2025, 00:20 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24. Dez. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24. Dez. 2025, 21:26 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Peer-Vergleich

Kursveränderung

Certara Inc Prognose

Kursziel

By TipRanks

41.28% Vorteil

12-Monats-Prognose

Durchschnitt 12.56 USD  41.28%

Hoch 16 USD

Tief 9 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Certara Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

6

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

11.27 / 12.79Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

359 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat